1. Purpose

This document outlines the guidelines and procedure details required for the testing of the presence and type of red cell antibodies during pregnancy.

2. Definitions

Not applicable.

3. Responsibilities

Clinicians (medical and midwifery staff) responsible for the testing of the presence and type of red cell antibodies during pregnancy should follow this guideline.

4. Guideline

A blood sample is taken from all pregnant women at their first antenatal visit in order to:

- test for the presence of red blood cell antibodies
- establish ABO and Rh D blood group types

If red cell antibodies are not detected, a repeat blood sample for the same tests is required in the third trimester, generally at 26 weeks gestation. Women who are known to be Rh Negative should have their testing performed through the Women's and Children's pathology service onsite.

A very small number of women are found to have antibodies which are more likely to affect the baby, e.g. Rh anti-D, anti-c and anti-K. More frequent blood samples will be necessary if these antibodies are present, or if there is any other cause for concern regarding the baby's wellbeing.

4.1 The objectives of testing in pregnancy

The objectives of routine blood group and antibody testing in pregnancy are to:

- identify Rh D negative women who would then require anti-D immunoglobulin prophylaxis
- detect and identify red blood cell antibodies
- identify pregnancies at risk of fetal and neonatal haemolytic disease resulting from clinically significant maternal antibodies crossing the placenta and entering the fetal circulation
- to identify antibodies which may be relevant to the safe provision of blood should it be required for transfusion.

When clinically significant red blood cell antibodies are present during pregnancy, follow-up antibody testing is necessary to:

- identify a fetus that may require treatment before term
- predict which infants might require treatment and should be monitored closely after birth
- detect and identify new antibodies, as those who develop one antibody are more likely to develop additional antibodies.

If an antibody is confirmed and is of clinical significance to the fetus, the antibody will be quantified or titrated and follow-up tests performed.

The follow-up investigations are:

- monitoring maternal red blood cell antibody levels
- identifying possible additional antibodies
- red blood cell phenotyping and genotyping (DNA analysis) of the father when necessary
- fetal genotyping (DNA analysis) if required.
### 4.2 Guide to routine red cell antibody screening

The results of the 1st screen at booking, guides the management pathway (see table below):

- those women with any Group 1 or Group 2 antibodies detected are to be referred to the MFM Consultant within the team for advice/ ongoing care
- Women with Group 3 antibodies can continue routine care. They require a group and antibody screen prior to caesarean birth, induction of labour or on admission to birth suite to facilitate safe blood provision should it be required.
- Women with no antibodies detected can continue routine care.
- Women whose blood group result is Rh D negative may be eligible to receive RhD Immunoglobulin.

Any concerns or queries should be raised with the on-call haematologist. Refer to CPG: [Anti D Immunoglobulin Use in Maternity Patients](#).

<table>
<thead>
<tr>
<th>Testing for All Women at Pregnancy Booking Clinic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group and Antibody screen</strong></td>
<td></td>
</tr>
<tr>
<td><strong>No Antibodies Detected</strong></td>
<td><strong>Antibodies Detected</strong></td>
</tr>
<tr>
<td>Repeat antibody screen on all women at 26 weeks gestation- visit at the Royal Women's Hospital or Community Clinics</td>
<td>If the Antibodies are:</td>
</tr>
<tr>
<td></td>
<td><strong>Group 1 antibody:</strong></td>
</tr>
<tr>
<td></td>
<td>(-D, -c, -E, -e, -C, -Fy(a), -K, -k)</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td><strong>Group 2 antibody:</strong></td>
</tr>
<tr>
<td></td>
<td>(-C(w), -Fy(b), -Jk(a), -Jk(b), -Jk(3), -S, -s, -M, -Ge(a))</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td><strong>Previous history of infant affected by HDN</strong></td>
</tr>
<tr>
<td></td>
<td>Refer to MFM consultant for advice/ pregnancy management.</td>
</tr>
<tr>
<td></td>
<td><strong>Group 3 antibody detected</strong></td>
</tr>
<tr>
<td></td>
<td>(-P1, -N, -H, -Le(a), -Le(b), -Le(a+), -Sd(a), -HLA)</td>
</tr>
<tr>
<td></td>
<td>Patient will require early group and screen when they come into labour or for CS</td>
</tr>
</tbody>
</table>
5. **Evaluation, monitoring and reporting of compliance to this guideline**

- Critical/notifiable results: when testing is performed at the RWH blood bank, a new group 1 antibody, or a two-fold rise in titre of a group 1 or 2 antibody will be phoned to the requesting clinician or team registrar.
- Management plans for women with clinically significant antibodies are reviewed at the monthly alloimmunisation group meeting.

6. **References**


7. **Legislation/Regulations related to this guideline**

Not applicable.

8. **Appendices**

Not applicable.

---

**PGP Disclaimer Statement**

The Royal Women's Hospital Clinical Guidelines present statements of 'Best Practice' based on thorough evaluation of evidence and are intended for health professionals only. For practitioners outside the Women's this material is made available in good faith as a resource for use by health professionals to draw on in developing their own protocols, guided by published medical evidence. In doing so, practitioners should themselves be familiar with the literature and make their own interpretations of it.

Whilst appreciable care has been taken in the preparation of clinical guidelines which appear on this web page, the Royal Women's Hospital provides these as a service only and does not warrant the accuracy of these guidelines. Any representation implied or expressed concerning the efficacy, appropriateness or suitability of any treatment or product is expressly negated.

In view of the possibility of human error and/or advances in medical knowledge, the Royal Women's Hospital cannot and does not warrant that the information contained in the guidelines is in every respect accurate or complete. Accordingly, the Royal Women's Hospital will not be held responsible or liable for any errors or omissions that may be found in any of the information at this site.

You are encouraged to consult other sources in order to confirm the information contained in any of the guidelines and, in the event that medical treatment is required, to take professional, expert advice from a legally qualified and appropriately experienced medical practitioner.

NOTE: Care should be taken when printing any clinical guideline from this site. Updates to these guidelines will take place as necessary. It is therefore advised that regular visits to this site will be needed to access the most current version of these guidelines.